DDInter1236 DDInter899
Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Modafinil {u} (Compound) resembles {v} (Compound) Fentanyl
Modafinil {u} (Compound) resembles {v} (Compound) Fenoprofen
Modafinil {u} (Compound) binds {v} (Gene) CYP1A2
Modafinil {u} (Compound) upregulates {v} (Gene) HP
Modafinil {u} (Compound) palliates {v} (Disease) multiple sclerosis
Modafinil {u} (Compound) is included by {v} (Pharmacologic Class) Central Nervous System Stimulation
Modafinil {u} (Compound) downregulates {v} (Gene) UBQLN2
Modafinil {u} (Compound) causes {v} (Side Effect) Hepatic enzyme increased
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pazopanib
Modafinil (Compound) resembles Fentanyl (Compound)
Modafinil (Compound) resembles Fenoprofen (Compound)
Modafinil (Compound) binds CYP1A2 (Gene)
Modafinil (Compound) upregulates HP (Gene)
Modafinil (Compound) palliates multiple sclerosis (Disease)
Modafinil (Compound) is included by Central Nervous System Stimulation (Pharmacologic Class)
Modafinil (Compound) downregulates UBQLN2 (Gene)
Modafinil (Compound) causes Hepatic enzyme increased (Side Effect)
Modafinil may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide
Modafinil may cause a minor interaction that can limit clinical effects when taken with Pazopanib